In 2023, the treatment success rate for extensively drug-resistant tuberculosis (XDR-TB) in India was recorded at 35%. Forecasts for 2024 to 2028 show a gradual improvement, with a projected increase to 37% by 2026, maintaining this rate through 2028. This indicates a 2% rise between 2023 and 2026. The compound annual growth rate (CAGR) over this five-year period is expected to be approximately 1.12%.
Future trends to watch for include advancements in diagnostic techniques, the introduction of newer, more effective drug regimens, and enhanced healthcare infrastructure, all of which could significantly impact treatment success rates. Attention to policy changes and funding for tuberculosis programs will also be crucial.
